...
首页> 外文期刊>Frontiers in Pediatrics >Primary Adrenocortical Insufficiency Case Series in the Neonatal Period: Genetic Etiologies Are More Common Than Expected
【24h】

Primary Adrenocortical Insufficiency Case Series in the Neonatal Period: Genetic Etiologies Are More Common Than Expected

机译:新生儿时期的原发性肾上腺皮质壳体系列:遗传病因比预期更常见

获取原文
           

摘要

Primary adrenocortical insufficiency (PAI) is an important cause of morbidity in neonates. The most common cause of PAI in neonates is congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency (21-OHD). Other rarer monogenic cases, for example, adrenal hypoplasia congenita (AHC) or familial glucocorticoid deficiency, also simulate clinical manifestation of 21-OHD, leading to misdiagnosis. The therapies and prognosis of these monogenic cases of PAI are entirely different. This study aimed to compare the differences of clinical data and identify genetic etiologies of PAI cases in the neonatal period. All 7 neonates initially presented with hyperpigmentation, hyponatremia, hyperkalemia, and high serum adrenocorticotropic hormone levels. Only CAH patients showed hyperandrogenism and remarkably elevated serum 17-hydroxyprogesterone levels. All the pathogenic mutations found in CYP21A2 were well known, except c.1069CT (exon 8). The male patient with AHC had a novel hemizygous deletion of exon 2 in DAX1. The other one with familial glucocorticoid deficiency type 1 had two novel heterozygous mutations in the gene coding melanocortin 2 receptor, c.701CT (exon 2) and c.119delT (exon 2). Glucocorticoid and/or mineralocorticoid replacement therapy depends on the cause of PAI. Genetic testing can be performed as a alternative diagnostic approach to provide information about therapy, prognosis, and genetic counseling.
机译:原发性肾上腺皮质不足(PAI)是新生儿发病率的重要原因。由于21-羟化酶缺乏(21-OHD),新生儿Pai最常见的原因是先天性肾上腺增生(CAH)。其他稀有的单一的病例,例如,肾上腺发育性同胞(AHC)或家族性糖皮质激素缺乏,也模拟了21-OHD的临床表现,导致误诊。这些单一的pai单身病例的疗法和预后完全不同。本研究旨在比较新生儿时期临床数据的差异和鉴定PAI病例的遗传学病因。所有7个新生儿最初呈现过度沉着过度沉着,低钠血症,高钾血症和高血清肾上腺皮质激素水平。只有CAH患者均显示高糖,血清17-羟丙酮水平显着升高。除了C.1069C> T(外显子8)之外,CYP21A2中发现的所有致病突变均为众所周知的。患有AHC的男性患者在DAX1中具有新的血液缺失的外显子2。具有家族性糖皮质激素缺乏型的另一个在基因编码Melanocortin 2受体中具有两种新的杂合突变,C.701c& t(外显子2)和C.119delt(外显子2)。糖皮质激素和/或矿物质激素替代疗法取决于PAI的原因。遗传测试可以作为替代诊断方法进行,提供有关治疗,预后和遗传咨询的信息。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号